DAMORA THERAPEUTICS, INC. Interest Income (Expense), Net
DAMORA THERAPEUTICS, INC. (DMRA) reported Interest Income (Expense), Net of $4.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2026-06-30 was $4.06M, a 8018.00% increase year-over-year.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2026-03-31 was $3.07M, a 4048.65% increase year-over-year.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2025-12-31 was $1.00M, a 339.04% increase year-over-year.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for the quarter ending 2025-09-30 was $42.00K, a 71.23% decline year-over-year.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for fiscal 2025 was $1.17M, a 38.27% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for fiscal 2024 was $844.00K, a 50.03% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for fiscal 2023 was $1.69M, a 133.93% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. interest income (expense), net for fiscal 2022 was $722.00K, a 362.82% increase from fiscal 2021.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.06M 10-Q · filed 2026-08-10 | $7.13M 10-Q · filed 2026-08-10 | $8.13M derived: sum of 3 quarters · filed 2026-08-10 | $8.17M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $3.07M 10-Q · filed 2026-05-12 | $4.07M derived: sum of 2 quarters · filed 2026-05-12 | $4.11M derived: sum of 3 quarters · filed 2026-05-12 | $4.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.04M derived: sum of 2 quarters · filed 2026-03-19 | $1.09M derived: sum of 3 quarters · filed 2026-08-10 | $1.17M 10-K · filed 2026-03-19 |
| 2025-09-30 | $42.00K 10-Q · filed 2025-11-06 | $92.00K derived: sum of 2 quarters · filed 2026-08-10 | $166.00K 10-Q · filed 2025-11-06 | $394.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-10 | $124.00K 10-Q · filed 2026-08-10 | $352.00K derived: sum of 3 quarters · filed 2026-08-10 | $498.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $74.00K 10-Q · filed 2026-05-12 | $302.00K derived: sum of 2 quarters · filed 2026-05-12 | $448.00K derived: sum of 3 quarters · filed 2026-05-12 | $661.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $374.00K derived: sum of 2 quarters · filed 2026-03-19 | $587.00K derived: sum of 3 quarters · filed 2026-03-19 | $844.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $146.00K 10-Q · filed 2025-11-06 | $359.00K derived: sum of 2 quarters · filed 2025-11-06 | $616.00K 10-Q · filed 2025-11-06 | $956.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $213.00K 10-Q · filed 2025-08-05 | $470.00K 10-Q · filed 2025-08-05 | $810.00K derived: sum of 3 quarters · filed 2025-08-05 | $1.28M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $257.00K 10-Q · filed 2025-05-08 | $597.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.07M derived: sum of 3 quarters · filed 2025-05-08 | $1.51M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $813.00K derived: sum of 2 quarters · filed 2025-03-19 | $1.25M derived: sum of 3 quarters · filed 2025-03-19 | $1.69M 10-K · filed 2025-03-19 |
| 2023-09-30 | $473.00K 10-Q · filed 2024-11-01 | $915.00K derived: sum of 2 quarters · filed 2024-11-01 | $1.35M 10-Q · filed 2024-11-01 | $1.63M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $442.00K 10-Q · filed 2024-08-12 | $876.00K 10-Q · filed 2024-08-12 | $1.16M derived: sum of 3 quarters · filed 2024-08-12 | $1.38M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $434.00K 10-Q · filed 2024-04-29 | $718.00K derived: sum of 2 quarters · filed 2024-04-29 | $939.00K derived: sum of 3 quarters · filed 2024-04-29 | $1.09M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $505.00K derived: sum of 2 quarters · filed 2024-03-08 | $661.00K derived: sum of 3 quarters · filed 2024-03-08 | $722.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $221.00K 10-Q · filed 2023-11-06 | $377.00K derived: sum of 2 quarters · filed 2023-11-06 | $438.00K 10-Q · filed 2023-11-06 | $468.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $156.00K 10-Q · filed 2023-07-31 | $217.00K 10-Q · filed 2023-07-31 | $247.00K derived: sum of 3 quarters · filed 2023-07-31 | $282.00K derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $61.00K 10-Q · filed 2023-04-28 | $91.00K derived: sum of 2 quarters · filed 2023-04-28 | $126.00K derived: sum of 3 quarters · filed 2023-04-28 | $178.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $65.00K derived: sum of 2 quarters · filed 2023-03-09 | $117.00K derived: sum of 3 quarters · filed 2023-03-09 | $156.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $35.00K 10-Q · filed 2022-11-08 | $87.00K derived: sum of 2 quarters · filed 2022-11-08 | $126.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $52.00K 10-Q · filed 2022-07-29 | $91.00K 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $39.00K 10-Q · filed 2022-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |